瑞思迈(RMD)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

RMD 瑞思迈

交易中 08-05 13:56:52 EDT

222.82

-0.32

-0.14%

最高224.99	最低220.49	成交量79.04万
今开223.30	昨收223.14	日振幅2.02%
总市值323.21亿	流通市值321.49亿	总股本1.45亿
成交额1.76亿	换手率0.55%	流通股本1.44亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"RMD","market":"US","secType":"STK","nameCN":"瑞思迈","latestPrice":222.82,"timestamp":1785952611174,"preClose":223.14,"halted":0,"volume":790390,"delay":0,"changeRate":-0.0014340772609124012,"floatShares":144284409,"shares":145056384,"eps":10.370449,"marketStatus":"交易中","change":-0.32,"latestTime":"08-05 13:56:52 EDT","open":223.295,"high":224.99,"low":220.49,"amount":176194592.42119998,"amplitude":0.020167,"askPrice":222.89,"askSize":103,"bidPrice":222.67,"bidSize":71,"shortable":3,"etf":0,"ttmEps":10.370449,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1785960000000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":223.14,"dividendRate":0.010771,"preHourTrading":{"tag":"盘前","latestPrice":222,"preClose":223.14,"latestTime":"09:18 EDT","volume":135,"amount":29999.889,"timestamp":1785935886710,"change":-1.14,"changeRate":-0.005109,"amplitude":0.011204},"postHourTrading":{"tag":"盘后","latestPrice":223.14,"preClose":223.14,"latestTime":"19:59 EDT","volume":65296,"amount":14570132.9,"timestamp":1785887992746,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.85659,"impliedVol":0.4819,"impliedVolPercentile":0.9841},"requestUrl":"/m/hq/s/RMD","defaultTab":"news","newsList":[{"id":"1195295414","title":"克利夫兰医疗设备公司：PTAB在五分之四的诉讼中裁定公司未能证明争议专利主张不可授权","url":"https://stock-news.laohu8.com/highlight/detail?id=1195295414","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195295414?lang=zh_cn&edition=full","pubTime":"2026-07-14 04:29","pubTimestamp":1783974574,"startTime":"0","endTime":"0","summary":"克利夫兰医疗设备公司披露，美国专利审判和上诉委员会（PTAB）在针对其五项专利诉讼中的四项，作出了对其有利的裁决，认定公司未能成功证明相关争议专利主张不具备可专利性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4504","BK4588","RMD","LU2177674079.SGD","BK4082","BK4567","BK4548","IE00B5TLWC47.USD","LU0170899867.USD","LU2008162690.USD","LGHT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186598906","title":"异动解读｜瑞思迈盘中下跌5.61%，花旗下调评级至中性引发抛压","url":"https://stock-news.laohu8.com/highlight/detail?id=1186598906","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186598906?lang=zh_cn&edition=full","pubTime":"2026-07-13 21:38","pubTimestamp":1783949931,"startTime":"0","endTime":"0","summary":"7月13日，瑞思迈盘中下跌5.61%，报196.975美元/股，成交额3231.34万美元。消息面上，花旗将瑞思迈评级从\"买入\"下调至\"中性\"，目标价定为34澳元，成为近期机构连续下调中最具冲击力的一次。此前，花旗曾于6月中旬将美股目标价从340美元降至270美元并维持买入，此次进一步降级至中性，反映对公司前景预期的实质性恶化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119046769","title":"异动解读｜瑞思迈盘前下跌5.19%，花旗下调评级至中性","url":"https://stock-news.laohu8.com/highlight/detail?id=1119046769","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119046769?lang=zh_cn&edition=full","pubTime":"2026-07-13 21:27","pubTimestamp":1783949262,"startTime":"0","endTime":"0","summary":"7月13日，瑞思迈盘前下跌5.19%，报193.01美元/股，成交额37.32万美元。消息面上，花旗将瑞思迈评级从\"买入\"下调至\"中性\"，目标价定为34澳元，为近期机构连续下调中最具冲击力的一次。此前，Jefferies已将目标价从240美元下调至225美元，Jarden将澳股目标价从42.70澳元降至40.20澳元。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144489423","title":"异动解读｜瑞思迈盘中下跌5.29%，宣布出售MatrixCare业务叠加RBC下调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1144489423","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144489423?lang=zh_cn&edition=full","pubTime":"2026-07-08 21:59","pubTimestamp":1783519151,"startTime":"0","endTime":"0","summary":"7月8日，瑞思迈盘中下跌5.29%，报208.52美元/股，成交额4511.7万美元。消息面上，公司宣布同意出售旗下MatrixCare业务，以聚焦高增长的睡眠及互联护理市场；同日RBC Capital将公司目标价从321美元大幅下调至276美元，维持跑赢大盘评级。此前一日公司因Noctrix收购消息推动曾上涨5.01%，当前回吐全部涨幅。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118172917","title":"瑞思迈重申2026财年非GAAP毛利率、销售管理费用、研发支出及非GAAP税率展望——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1118172917","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118172917?lang=zh_cn&edition=full","pubTime":"2026-07-08 05:31","pubTimestamp":1783459908,"startTime":"0","endTime":"0","summary":"瑞思迈在提交给美国证券交易委员会（SEC）的最新文件中，重申了其对2026财年多项关键财务指标的非公认会计准则（Non-GAAP）展望。公司确认的预期目标范围涵盖非GAAP毛利率、销售管理费用（SG&A）、研发（R&D）支出以及非GAAP税率。\n此举表明管理层对既定运营与财务计划保持信心，预计相关成本结构与盈利能力将沿预设轨迹发展。市场通常关注此类重申，视其为业务稳定性和预测能见度的信号。投资者可借此评估公司在呼吸与睡眠医疗设备领域的持续运营效率及长期财务健康度。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RMD","BK4585","LU2177674079.SGD","LU2008162690.USD","LGHT","BK4588","IE00B5TLWC47.USD","BK4548","BK4567","BK4504","LU0170899867.USD","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144595286","title":"异动解读｜瑞思迈盘中上涨5.01%，收购Noctrix扩展睡眠产品线叠加财报预期提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1144595286","media":"行情直击","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144595286?lang=zh_cn&edition=full","pubTime":"2026-07-07 02:11","pubTimestamp":1783361500,"startTime":"0","endTime":"0","summary":"7月7日，瑞思迈盘中上涨5.01%，报220.17美元/股，成交额4.26亿美元。消息面上，公司近期以3.4亿美元完成对Noctrix Health的收购，将FDA批准的非药物不宁腿综合征疗法纳入产品组合，拓展至第三大睡眠障碍治疗领域。该疗法将接入瑞思迈全球超2700万台云端互联设备生态，形成商业协同。此外，公司已公告将于8月6日发布第四季度财报，市场预期每股收益2.9美元。此前股价受摩根士丹利下调评级至等权重影响一度跌至52周低位附近，目前呈现明显反弹修复态势。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644749109","title":"大摩下调瑞思迈 (RMD) 投资评级 指减肥药与竞品入市双重压制其增长空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2644749109","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2644749109?lang=zh_cn&edition=full","pubTime":"2026-06-17 21:05","pubTimestamp":1781701559,"startTime":"0","endTime":"0","summary":"机构同步下调盈利测算与估值目标，报告测算瑞思迈2027 财年净利润同比增速约 5%，仅小幅高于市场 4% 的一致预期，远低于企业近三年 19% 的每股收益复合增速。该行将目标价自 286 美元下调至 230 美元，提示竞品回归、减重药物渗透将长期限制企业估值修复空间。","market":"us","thumbnail":"https://static.szfiu.com/news/20210810/NjViMmRjZjhjOGM5NGFlMzkzMTgwODQxMTc3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NjViMmRjZjhjOGM5NGFlMzkzMTgwODQxMTc3.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"301645","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4082","BK4504","LU2008162690.USD","BK4585","BK4588","LU0170899867.USD","RMD","IE00B5TLWC47.USD","BK4567","LU2177674079.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111823360","title":"瑞思迈斥资3.4亿美元收购Noctrix Health，安杰利尼风投迎来首笔投资退出","url":"https://stock-news.laohu8.com/highlight/detail?id=1111823360","media":"美股速递","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111823360?lang=zh_cn&edition=full","pubTime":"2026-06-03 19:42","pubTimestamp":1780486964,"startTime":"0","endTime":"0","summary":"安杰利尼风投迎来了其投资组合中的首笔成功退出。医疗设备巨头瑞思迈已同意以高达3.4亿美元的全现金交易，收购专注于睡眠障碍治疗的初创公司Noctrix Health。交易完成后，瑞思迈将把Noctrix Health的技术整合进其现有的睡眠健康解决方案中，以加强其在睡眠呼吸暂停及其他睡眠障碍治疗领域的市场地位。Noctrix Health开发的创新神经刺激疗法，旨在为传统治疗方案效果不佳的患者提供新的选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4504","LU2008162690.USD","LU2177674079.SGD","BK4585","LU0170899867.USD","BK4567","IE00B5TLWC47.USD","BK4588","BK4082","BK4548","RMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173709534","title":"异动解读｜瑞思迈盘中下跌5.08%，宣布重大收购切入新赛道引发市场担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1173709534","media":"行情直击","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173709534?lang=zh_cn&edition=full","pubTime":"2026-05-30 03:01","pubTimestamp":1780081295,"startTime":"0","endTime":"0","summary":"5月29日，瑞思迈盘中下跌5.08%，报193.08美元/股，成交额2.75亿美元。消息面上，公司宣布重大收购，作为医疗器械巨头正式切入新赛道。市场对此次收购反应偏负面，投资者担忧收购可能带来整合风险及短期资金压力，叠加当前股价已从52周高点293.81美元大幅回落，市场情绪较为脆弱。同行业中，美敦力跌1.98%、波士顿科学跌1.66%、雅培跌0.67%，板块整体承压。瑞思迈是全球领先的呼吸系统医疗设备及云端软件公司，主要诊断、治疗和管理睡眠呼吸障碍、慢性阻塞性肺病等慢性疾病。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166757899","title":"财报前瞻｜瑞思迈本季度营收预计增10.39%，机构观点偏乐观","url":"https://stock-news.laohu8.com/highlight/detail?id=1166757899","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166757899?lang=zh_cn&edition=full","pubTime":"2026-04-23 09:48","pubTimestamp":1776908918,"startTime":"0","endTime":"0","summary":"瑞思迈将于2026年4月30日公布最新季度业绩，市场聚焦营收与利润增速的延续性及盈利质量变化。市场一致预期本季度瑞思迈营收为14.20亿美元，同比增长10.39%；调整后每股收益为2.80美元，同比增长18.74%；公司上季度未披露本季度明确量化指引，且目前缺乏一致口径的毛利率与净利率预测，相关指标暂未纳入。基于覆盖机构的经营模型，息税前利润预计为5.15亿美元，同比增长18.32%，反映费用效率与产品结构的持续优化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜瑞思迈本季度营收预计增10.39%，机构观点偏乐观","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627050257","title":"瑞思迈调查：49%中国受访者认为好睡眠是长寿和健康的最重要因素","url":"https://stock-news.laohu8.com/highlight/detail?id=2627050257","media":"中国经营报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2627050257?lang=zh_cn&edition=full","pubTime":"2026-04-16 10:21","pubTimestamp":1776306106,"startTime":"0","endTime":"0","summary":"“睡眠健康正在成为越来越多中国家庭关注的长期议题。”瑞思迈（Resmed）大中华区总经理李杨阳日前在接受《中国经营报》记者采访时表示，全球84%的受访者认为持续高质量睡眠有助于延长健康寿命，不过这一认知尚未转化为实际成果。全球领先健康科技公司瑞思迈一项覆盖13个市场和地区共3万人的全球睡眠调查显示，53%的受访者每周仅有4晚或更少获得高质量睡眠。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604163707102274.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604163707102274.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","BK4585","LU2177674079.SGD","BK4548","BK4504","LU2008162690.USD","RMD","IE00B5TLWC47.USD","BK4567","BK4082","LU0170899867.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627298283","title":"瑞思迈(RMD)盘前下跌3.91% 机构下调目标价至255美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2627298283","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2627298283?lang=zh_cn&edition=full","pubTime":"2026-04-15 18:17","pubTimestamp":1776248252,"startTime":"0","endTime":"0","summary":"金吾财讯 | 瑞思迈(RMD)盘前下跌3.91%，截至发稿，报221.67美元。消息面上，近日该公司董事、董事长兼首席执行官Michael·J·Farrell出售了4991股公司股票，交易金额约112.55万美金。此外，瑞穗证券分析师Anthony Petrone近期虽维持对瑞思迈的“买入”评级，但将目标价从300美元下调至255美元。","market":"other","thumbnail":"https://static.szfiu.com/news/20250107/Y2FiZWYxZjczOGJiNGFjYzNlMjE4NjgxMTg3ODM4OTg=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/Y2FiZWYxZjczOGJiNGFjYzNlMjE4NjgxMTg3ODM4OTg=.png"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"299235","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RMD","UUP","UDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627470966","title":"瑞思迈新一代持续正压通气治疗机在中国大陆上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2627470966","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2627470966?lang=zh_cn&edition=full","pubTime":"2026-04-15 12:51","pubTimestamp":1776228668,"startTime":"0","endTime":"0","summary":"南方财经4月15日电，记者获悉，专注于家庭睡眠、呼吸及护理的全球领先健康科技公司瑞思迈（Resmed）今日宣布新一代持续正压通气治疗机（CPAP）AirSense11正式在中国大陆上市。据介绍，全新AirSense11是瑞思迈迄今最具创新性的睡眠呼吸机产品之一，致力于为中国用户带来“看起来简单，用起来更简单”的全新智慧体验，通过“五维智慧升级”，从设计到智控全面进化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604153705709727.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604153705709727.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4548","LU0170899867.USD","RMD","LU2008162690.USD","IPOS","BK4504","IE00B5TLWC47.USD","LU2177674079.SGD","BK4588","BK4567","BK4082","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517887942","title":"瑞思迈盘中异动 临近午盘大幅下挫5.00%报219.92美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517887942","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517887942?lang=zh_cn&edition=full","pubTime":"2025-03-06 00:50","pubTimestamp":1741193455,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日00时50分，瑞思迈股票出现异动，股价急速跳水5.00%。截至发稿，该股报219.92美元/股，成交量44.8975万股，换手率0.31%，振幅3.42%。机构评级方面，在所有28家参与评级的机构中，64%的券商给予买入建议，32%的券商给予持有建议，4%的券商给予卖出建议。瑞思迈股票所在的医疗设备行业中，整体跌幅为0.35%。瑞思迈公司简介：瑞思迈是全球最大的呼吸护理设备公司之一，主要开发和供应用于治疗睡眠呼吸暂停的气流发生器、面罩和配件。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306005056abe9dade&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306005056abe9dade&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4504","BK4585","LU2177674079.SGD","BK4548","LU2008162690.USD","BK4082","RMD","BK4567","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517949213","title":"花旗：上调ResMed(RMD.US)评级，由中性调整至买入评级。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517949213","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517949213?lang=zh_cn&edition=full","pubTime":"2025-03-06 00:12","pubTimestamp":1741191126,"startTime":"0","endTime":"0","summary":"花旗：上调ResMed(RMD.US)评级，由中性调整至买入评级。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/06001248550397.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["RMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507964573","title":"Piper Sandler：维持ResMed(RMD.US)评级，由中性调整至中性评级, 目标价由252.00美元调整至260.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2507964573","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2507964573?lang=zh_cn&edition=full","pubTime":"2025-01-31 23:42","pubTimestamp":1738338122,"startTime":"0","endTime":"0","summary":"Piper Sandler：维持ResMed(RMD.US)评级，由中性调整至中性评级, 目标价由252.00美元调整至260.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/31234247922297.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["RMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507966535","title":"瑞思迈盘中异动 快速下跌5.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2507966535","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2507966535?lang=zh_cn&edition=full","pubTime":"2025-01-31 22:34","pubTimestamp":1738334059,"startTime":"0","endTime":"0","summary":"北京时间2025年01月31日22时34分，瑞思迈股票出现异动，股价大幅下跌5.23%。机构评级方面，在所有28家参与评级的机构中，68%的券商给予买入建议，29%的券商给予持有建议，3%的券商给予卖出建议。瑞思迈股票所在的医疗设备行业中，整体跌幅为0.27%。最近的发展和收购都集中在数字健康上，因为瑞思迈的目标是通过提供临床数据供院外环境中的患者、医疗保健顾问和付款人使用来实现差异化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250131223419abbe3c2f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250131223419abbe3c2f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2177674079.SGD","BK4082","LU2008162690.USD","BK4548","BK4585","RMD","BK4567","BK4588","BK4504"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146101037","title":"ResMed 2025第二季度调整后每股收益2.43美元，高于预期2.32美元，销售额为12.8亿美元，高于预期12.7亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1146101037","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146101037?lang=zh_cn&edition=full","pubTime":"2025-01-31 05:08","pubTimestamp":1738271326,"startTime":"0","endTime":"0","summary":"ResMed报告称，其季度每股收益为2.43美元，较分析师预期的2.32美元高出4.74％。与去年同期的每股收益1.88美元相比，这一数字增加了29.26％。以上内容来自Benzinga Earnings专栏，原文如下：ResMed  reported quarterly earnings of $2.43 per share which beat the analyst consensus estimate of $2.32 by 4.74 percent. This is a 29.26 percent increase over earnings of $1.88 per share from the same period last year.  The company reported quarterly sales of $1.28 billion which beat the analyst consensus estimate of $1.27 billion by 1.15 percent.  This is a 10.23 percent increase over","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"ResMed 2025第二季度调整后每股收益2.43美元，高于预期2.32美元，销售额为12.8亿美元，高于预期12.7亿美元","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2502634718","title":"ResMed获Piper Sandler首次覆盖","url":"https://stock-news.laohu8.com/highlight/detail?id=2502634718","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2502634718?lang=zh_cn&edition=full","pubTime":"2025-01-10 20:45","pubTimestamp":1736513154,"startTime":"0","endTime":"0","summary":"ResMed(RMD.US)获Piper Sandler首次覆盖，给予中性评级,目标价252.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250110210649aba5edfd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250110210649aba5edfd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4504","LU2008162690.USD","LU2177674079.SGD","BK4585","BK4567","BK4588","BK4082","BK4548","RMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2494820762","title":"瑞思迈：构建数字健康生态系统 全球龙头有望继续发力","url":"https://stock-news.laohu8.com/highlight/detail?id=2494820762","media":"中金公司","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2494820762?lang=zh_cn&edition=full","pubTime":"2024-12-27 00:00","pubTimestamp":1735228800,"startTime":"0","endTime":"0","summary":"Frost & Sullivan 数据显示，随着老龄化和空气污染的加剧，全球呼吸及睡眠相关疾病的患者数在持续增加。公司为家用无创呼吸机全球领导者。公司积极构筑数字健康生态系统，提升患者体验并实现降本增效。我们认为，公司通过整合软件服务产品和呼吸健康医疗器械，搭建数字健康生态系统，有望推动设备、面罩及其他耗材收入实现良好增长态势。风险政策风险，知识产权风险，竞争加剧风险，海外经营风险，产品召回风险，商誉减值风险。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241227151132ab946c80&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241227151132ab946c80&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","LU2008162690.USD","RMD","BK4548","BK4567","BK4504","LU2177674079.SGD","BK4585","BK4082"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.resmed.com","stockEarnings":[{"period":"1week","weight":0.0679},{"period":"1month","weight":0.0644},{"period":"3month","weight":0.0644},{"period":"6month","weight":-0.1644},{"period":"1year","weight":-0.2344},{"period":"ytd","weight":-0.0736}],"compareEarnings":[{"period":"1week","weight":0.0411},{"period":"1month","weight":0.0356},{"period":"3month","weight":0.0511},{"period":"6month","weight":0.1383},{"period":"1year","weight":0.2221},{"period":"ytd","weight":0.1311}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"ResMed Inc.是一家特拉华州公司，成立于1994年3月。该公司在医疗设备和基于云的软件应用程序的开发、制造、分销和营销方面处于全球领先地位，这些应用程序诊断、治疗和管理呼吸系统疾病，包括睡眠呼吸障碍、慢性阻塞性肺病、神经肌肉疾病和其他慢性疾病。该公司的产品和解决方案旨在改善患者的生活质量，减少慢性病的影响，并降低医疗保健成本，因为全球医疗保健系统继续推动从医院到家庭和低成本环境的护理转移。该公司基于云的数字软件健康应用程序以及设备旨在提供联网护理，以改善患者的治疗效果并提高客户的效率。","yearOnYearQuotes":[{"month":1,"riseRate":0.709677,"avgChangeRate":0.025332},{"month":2,"riseRate":0.516129,"avgChangeRate":0.002251},{"month":3,"riseRate":0.580645,"avgChangeRate":0.012701},{"month":4,"riseRate":0.548387,"avgChangeRate":0.014374},{"month":5,"riseRate":0.612903,"avgChangeRate":0.008895},{"month":6,"riseRate":0.7,"avgChangeRate":0.040489},{"month":7,"riseRate":0.741935,"avgChangeRate":0.029736},{"month":8,"riseRate":0.625,"avgChangeRate":0.029953},{"month":9,"riseRate":0.387097,"avgChangeRate":0.015614},{"month":10,"riseRate":0.387097,"avgChangeRate":-0.004331},{"month":11,"riseRate":0.774194,"avgChangeRate":0.034364},{"month":12,"riseRate":0.580645,"avgChangeRate":0.018091}],"exchange":"NYSE","name":"瑞思迈","nameEN":"ResMed"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"瑞思迈(RMD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供瑞思迈(RMD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"瑞思迈,RMD,瑞思迈股票,瑞思迈股票老虎,瑞思迈股票老虎国际,瑞思迈行情,瑞思迈股票行情,瑞思迈股价,瑞思迈股市,瑞思迈股票价格,瑞思迈股票交易,瑞思迈股票购买,瑞思迈股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"瑞思迈(RMD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供瑞思迈(RMD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}